Product Information
EDARBI 40 MG TABLET is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $8.2848 per EA under NDC 60631004030. Its NADAC has been published 619 times since Nov 26, 2014.
FDA first approved this application on Feb 25, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Azurity Pharmaceuticals Inc.NDC
60631004030
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AZILSARTAN KAMEDOXOMILApproval Type
New Drug (NDA)
FDA Application
NDA200796FDA Approved
2/25/2011
TE Code
AB
On Market Since
2/1/2013
Pharmacological Classes
Price Statistics
The NADAC for EDARBI 40 MG TABLET has been published 619 times since Nov 26, 2014, and over the history we have for it it has risen 106.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.2848 per EA |
|---|---|
| All-time high | $8.3010 (Sep 10, 2025) |
| All-time low | $4.0087 (Nov 26, 2014) |
| 52-week high | $8.2981 |
| 52-week low | $8.2828 |
| Median price | $6.2775 |
| Average price | $6.3842 |
| Largest weekly change | +10.0% (Feb 11, 2015) |
| Weeks tracked | 619 |
| Tracking since | Nov 26, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Azilsartan kamedoxomil market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Azilsartan kamedoxomil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EDARBI 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EDARBI 40 MG TABLET, manufactured by Azurity Pharmaceuticals Inc., is $8.2848 per EA (NDC 60631004030), effective Sep 30, 2026.
How has the price of EDARBI 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for EDARBI 40 MG TABLET has risen 106.7%. It has been tracked across 619 weekly CMS publications since Nov 26, 2014.
What are the highest and lowest recorded NADAC prices for EDARBI 40 MG TABLET?
Since Nov 26, 2014, the NADAC for EDARBI 40 MG TABLET has ranged from a low of $4.0087 (Nov 26, 2014) to a high of $8.3010 (Sep 10, 2025), with a median of $6.2775 per EA.
Are there cheaper alternatives to EDARBI 40 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of EDARBI 40 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EDARBI 40 MG TABLET?
EDARBI 40 MG TABLET (NDC 60631004030) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.